Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CHNR vs ABCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CHNR Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

CHNR Overall Winner 6-Pillar Tally: CHNR 5 – 1 ABCL Matrix Metrics: CHNR 6 – 4 ABCL

As of Nov 20, 2026, China Natural Resources, Inc. (CHNR) is the stronger overall head-to-head candidate over AbCellera Biologics Inc. Common Shares (ABCL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CHNR carries a Unified Composite Score of 43.4/100 (HOLD) at $2.98 (7.8x Forward P/E, 0.0% operating margin), whereas ABCL carries 57.1/100 (HOLD) at $9.69 (27.6x Forward P/E, -298.0% operating margin).

  • Composite vs. Pillar Nuance: While ABCL currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. CHNR 43.4/100 HOLD), CHNR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -298.0% operating margin) and revenue trajectory (-24.0% vs. +18.8% YoY).
  • Technical & Structure Timing Caution: CHNR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.2); meanwhile ABCL is in a Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CHNR vs ABCL
CHNR NASDAQ Head-to-Head Winner
China Natural Resources, Inc.
Wholesale-Miscellaneous Nondurable Goods
$2.98
-0.33% 1D
Market Cap $3.8M
TTM Revenue $16M
Forward P/E 7.8x
Beta / 30D Vol 1.15β · 53% Vol
Unified Composite Score
43.4 / 100 HOLD
Tech 35.0 Fund 42.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 21
RSI-14: 21.2 · SMA20: $3.78 · SMA50: $3.85
ABCL NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$9.69
-7.45% 1D
Market Cap $3.4B
TTM Revenue $68M
Forward P/E 27.6x
Beta / 30D Vol 2.32β · 85% Vol
Unified Composite Score
57.1 / 100 HOLD
Tech 33.0 Fund 54.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 33.8 · SMA20: $11.79 · SMA50: $12.30

6-Pillar Scorecard Institutional Category Breakdown (CHNR 5 – 1 ABCL)

Columns: Metric · CHNR · ABCL
1. Valuation Multiples CHNR
Forward P/E 7.8x 27.6x
Trailing P/E 7.8x 27.6x
PEG Ratio 0.30x N/M
EV / Revenue 0.2x 50.0x
2. Growth & Scale ABCL
Revenue Growth (YoY) -24.0% +18.8%
Earnings Growth (YoY) +0.0% +45.9%
TTM Revenue (USD) $16M $68M
Market Cap $3.8M $3.4B
3. Profitability & Quality CHNR
Gross Margin 1.5% N/A
Operating Margin 0.0% -298.0%
Net Profit Margin 0.0% -218.6%
Return on Equity (ROE) -1.4% -14.6%
4. Balance Sheet & Cash Flow CHNR
Cash Generation (TTM) -$3.3M EBITDA -$33M
Cash Flow Margin -20.0% EBITDA Mgn -48.4%
Net Cash / Leverage $10.29 Book/Sh · -1.4% ROE $30M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CHNR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 86.5% (32nd %ile)
Put/Call OI Skew N/A 0.35x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat CHNR
OpEx & R&D Intensity 1.5% of Rev ($246,750) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Other Industrial Metals & Mining Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CHNR (6) vs ABCL (4)
Institutional Metric CHNR ABCL Criterion Row Edge
Market Capitalization
Scale
$3.8M $3.4B Larger Scale ABCL
Trailing P/E Ratio
Valuation
7.8x 27.6x Lower Multiple CHNR
Forward P/E Ratio
Valuation
7.8x 27.6x Lower Multiple CHNR
Revenue Growth (YoY)
Growth
-24.0% +18.8% Higher Growth ABCL
Operating Margin (TTM)
Profitability
0.0% -298.0% Higher Margin CHNR
Net Profit Margin
Profitability
0.0% -218.6% Higher Margin CHNR
Return on Equity (ROE)
Capital Efficiency
-1.4% -14.6% Higher ROE CHNR
52-Week Range Position
Momentum
0% ($3–$6) 57% ($3–$15) Stronger Trend ABCL
Beta / 30D Volatility
Risk Regime
1.15β · 53% Vol 2.32β · 85% Vol Lower Realized Risk CHNR
Unified Institutional Score
Composite Signal
43.4 / 100 (HOLD) 57.1 / 100 (HOLD) Higher Composite ABCL
Trailing 12M Revenue (USD)
Operating Scale
$16M $68M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
1.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.30x PEG · 0.2x EV/Rev N/M PEG · 50.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.3M EBITDA ($10.29 Book/Sh · -1.4% ROE) -$33M ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABCL +8.36 pp
CHNR: -26.24% · ABCL: -17.88%
3M Horizon ABCL +13.69 pp
CHNR: -28.54% · ABCL: -14.85%
6M Horizon ABCL +152.35 pp
CHNR: -32.12% · ABCL: +120.23%
1Y Horizon ABCL +184.73 pp
CHNR: -16.31% · ABCL: +168.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CHNR vs ABCL. Trailing 12-month operating profitability (CHNR 0.0% vs ABCL -298.0%) and valuation multiples (CHNR 7.8x vs ABCL 27.6x Forward P/E) are benchmarked directly in Pillar 4 below.

CHNR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$16M
Gross Margin1.5%
Op. Margin0.0%
ROE / Fwd P/E-1.4% · 7.8x
ABCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$68M
Gross MarginN/A
Op. Margin-298.0%
ROE / Fwd P/E-14.6% · 27.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CHNR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CHNR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABCL BREAKDOWN
38d in phase · OBV DISTRIBUTION
Current IV 86.5%
IV Percentile 32nd %ile
Put/Call OI Skew 0.35x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $11.12 · IV 84.0%

ABCL Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,112)

Compare $1,112 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 84.0% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $12 / $13 Bull Call Spread

Buy 4x $12C · Sell 4x $13C · 32d

Net Entry $80 Debit
T+5d @ +5% Move +$25 (+31%)
Max Risk / Buffer $80 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Jan 15 '27 $10 / $9 Bull Put Spread

Sell 5x $10P · Buy 5x $9P · 60d

Net Entry $175 Credit
Max Credit / Yield +$175 (+53.8% RoM)
Max Risk / Buffer -13.2% Cushion ($325 Mgn)
5d Edge & Liquidity 70% PoP · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq B

Dec 18 $12 / $10 Bear Put Spread

Buy 1x $12P · Sell 1x $10P · 32d

Net Entry $106 Debit
T+5d @ -5% Drop +$16 (+15%)
Max Risk / Buffer $106 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CHNR Moat Profile Cyclical / Execution-Driven Positioning
Other Industrial Metals & Mining Operator
Competes within the Other Industrial Metals & Mining value chain with $3.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment 1.5% of Rev ($246,750)
90D Engineering Disclosures 0 Published
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.4B market capitalization and -298.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CHNR vs ABCL Key Questions & Quantitative Answers

As of Nov 20, 2026, China Natural Resources, Inc. (CHNR) is the stronger overall head-to-head candidate over AbCellera Biologics Inc. Common Shares (ABCL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CHNR carries a Unified Composite Score of 43.4/100 (HOLD) at $2.98 (7.8x Forward P/E, 0.0% operating margin), whereas ABCL carries 57.1/100 (HOLD) at $9.69 (27.6x Forward P/E, -298.0% operating margin). Composite vs. Pillar Nuance: While ABCL currently prints a higher short-term Unified Composite Score (57.1/100 HOLD vs. CHNR 43.4/100 HOLD), CHNR captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -298.0% operating margin) and revenue trajectory (-24.0% vs. +18.8% YoY). Technical & Structure Timing Caution: CHNR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.2); meanwhile ABCL is in a Breakdown options structure phase (RSI 33.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABCL leads the Growth & Scale pillar: CHNR posts -24.0% YoY revenue growth and +0.0% YoY earnings growth on $16M TTM revenue (1.5% gross margin, 0.0% operating margin), compared with ABCL at +18.8% YoY revenue growth and +45.9% YoY earnings growth on $68M TTM revenue (N/A gross margin, -298.0% operating margin). On trailing 12-month operating scale, CHNR generates $16M in USD-normalized revenue versus $68M for ABCL. In operating R&D and SG&A reinvestment, CHNR deploys 1.5% of Rev ($246,750) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.

CHNR screens cheaper on headline valuation multiples. CHNR trades at 7.8x Forward P/E, 7.8x Trailing P/E, 0.30x PEG, and 0.2x EV/Revenue (-20.0% EBITDA margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 50.0x EV/Revenue (-48.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CHNR (-1.4% ROE) versus ABCL (-14.6% ROE) capital efficiency.

In options market volatility and institutional positioning, CHNR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.15β · 53% Vol realized risk). By comparison, ABCL carries 86.5% implied volatility (32nd %ile, Balanced (25th–60th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.32β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.